Budesonide
- Generic Name
- Budesonide
- Brand Names
- Airsupra, Breyna, Breztri, Cortiment, Entocort, Pulmicort, Pulmicort Turbuhaler, Rhinocort, Symbicort, Tarpeyo, Uceris, Jorveza, Kinpeygo
- Drug Type
- Small Molecule
- Chemical Formula
- C25H34O6
- CAS Number
- 51333-22-3
- Unique Ingredient Identifier
- Q3OKS62Q6X
- Background
Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.
Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product with formoterol.
- Indication
Budesonide extended release capsules are indicated for the treatment and maintenance of mild to moderate Crohn’s disease. Various inhaled budesonide products are indicated for prophylactic therapy in asthma and to reduce exacerbations of COPD. A budesonide nasal spray is available over the counter for symptoms of hay fever and upper respiratory allergies. E...
- Associated Conditions
- Allergic Reaction, Allergic Rhinitis (AR), Asthma, Bronchoconstriction, Chronic Obstructive Pulmonary Disease (COPD), Collagenous Colitis, Crohn's Disease (CD), Eosinophilic Esophagitis, Exacerbation of asthma, Nasal Congestion, Nasal Polyps, Proteinuria, Pruritus, Rhino Sinusitis, Ulcerative Colitis, Vasomotor Rhinitis, Corticosteroid-responsive dermatoses, Mild Crohn’s Disease, Moderate Crohn’s Disease
- Associated Therapies
- Maintenance therapy
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
- Conditions
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Medical University of Warsaw
- Target Recruit Count
- 114
- Registration Number
- NCT06719622
- Locations
- 🇵🇱
Jagiellonian University, Kraków, Poland
🇵🇱Poznań University of Medical Sciences, Poznań, Poland
🇵🇱Medical University of Warsaw, Warsawa, Poland
Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Target Recruit Count
- 308
- Registration Number
- NCT06596252
- Locations
- 🇪🇸
Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain
Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Unither Pharmaceuticals, France
- Target Recruit Count
- 24
- Registration Number
- NCT06595121
- Locations
- 🇹🇷
Farmagen IKU Merkezi, Gaziantep, Turkey
Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS
- Conditions
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 60
- Registration Number
- NCT06367881
- Locations
- 🇪🇬
Egypt Neonatal Intensive Care Units (NICUs), Ain Shams University Cairo, Abbasia, Egypt, 11517, Cairo, Egypt
Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels
- Conditions
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Maria Joyera Rodríguez
- Target Recruit Count
- 135
- Registration Number
- NCT06334575
- Locations
- 🇬🇧
University of Leicester, Leicester, United Kingdom
🇪🇸Son Espases, Palma De Mallorca, Spain
🇪🇸Clínic Barcelona, Barcelona, Spain
A Study to Determine the Effect Food Has on TAK-721 (Budesonide Oral Suspension) in the Body of Healthy Adults
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT06268301
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Comparison of Preoperative Inhaled Budesonide With Salbutamol on the Respiratory Adverse Effects in Children Undergoing Tonsillectomy
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 87
- Registration Number
- NCT06158893
The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis
- Conditions
- Interventions
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Kafrelsheikh University
- Target Recruit Count
- 120
- Registration Number
- NCT05931744
- Locations
- 🇪🇬
Kafrelsheikh University hospital, Kafrelsheikh, Egypt
Dupilumab in Chinese Adult Participants With CRSwNP
- Conditions
- Interventions
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 63
- Registration Number
- NCT05878093
- Locations
- 🇨🇳
Investigational Site Number : 1560016, Jinan, China
🇨🇳Investigational Site Number : 1560001, Beijing, China
🇨🇳Investigational Site Number : 1560010, Chengdu, China
Predicting Post Extubation Stridor After Maxillomandibular Fixation
- Conditions
- Interventions
- First Posted Date
- 2023-05-03
- Last Posted Date
- 2024-02-06
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 62
- Registration Number
- NCT05839756
- Locations
- 🇪🇬
Maha Ahmed AboZeid, Mansoura, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.